by Maria Zannes | Feb 5, 2019 | Press Releases
FEBRUARY 4, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, announced that the Canadian Intellectual Property Office has awarded a patent expanding the Company’s claims associated with its proprietary CyPath© technology for the early...
by Maria Zannes | Oct 23, 2018 | Press Releases
OCTOBER 23, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that the South Texas Veterans Health Care System (STVHCS), which is affiliated with the federal Department of Veterans Affairs (VA) health care system, will...
by Maria Zannes | Oct 12, 2018 | Press Releases
OCTOBER 10, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced a licensing agreement with Precision Pathology Services for the continued development and commercial sale of CyPath® Lung as a Laboratory Developed Test...
by Maria Zannes | Sep 22, 2018 | Press Releases
SEPTEMBER 18, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY, will be a clinical collection site for the Company’s test validation trial of...
by Maria Zannes | Aug 1, 2018 | Press Releases
JULY 31, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Mohsin Y. Meghji, managing partner of M-III Partners L.P. (M-III), to its Board of...
by Maria Zannes | Jul 23, 2018 | Press Releases
JULY 17, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has commenced its test validation trial for CyPath® Lung, an advanced flow cytometry test for the early detection of lung cancer. Recruitment is...
